Mary-Claire King helped establish that inherited breast cancer susceptibility could be mapped to a specific region of the genome. In 1990, her team’s linkage research localized a major susceptibility locus to chromosome 17q21, laying the groundwork for the later identification of BRCA1. The discovery began with a question about family patterns, years before routine clinical genetic testing.
The challenge was extraordinary for the time. The human genome had not been sequenced. There was no routine clinical genetic test for hereditary breast cancer. Researchers had to infer the existence and location of a susceptibility gene from family histories, inheritance patterns, and genetic markers. NCI: Mary-Claire King
How family data pointed to inherited susceptibility
King’s work in the 1970s and 1980s combined epidemiology, mathematics, and genetics. Family data suggested that a subset of breast cancers could be explained by a highly penetrant inherited factor. The scientific question became: if such a gene exists, can its inheritance be tracked through families strongly enough to map it to a chromosome?
This is an important part of the discovery story because it shows that the gene was not first found by sequencing thousands of tumors. The evidence for inherited susceptibility came from patterns in families and linkage analysis.
Mapping the BRCA1 region in 1990
In 1990, King and colleagues reported linkage of early-onset familial breast cancer to chromosome 17q21. The result provided strong evidence for a major inherited susceptibility locus in that region. Hall et al. 1990
The paper did not yet identify the BRCA1 DNA sequence. Mapping and cloning are different achievements. Mapping narrows the search to a genomic region; cloning identifies the gene itself. That distinction matters because the four years between those steps required enormous additional work by multiple groups.
Identifying the BRCA1 gene in 1994
In 1994, Miki and colleagues reported a strong candidate for the BRCA1 susceptibility gene using positional cloning. Harmful variants were identified in families thought to carry BRCA1-linked susceptibility. The result turned a chromosomal location into a defined gene that could be sequenced, tested, and studied mechanistically. Miki et al., Science (1994)
The distinction also helps credit the science accurately: King’s team established the linkage and proved that an inherited susceptibility locus existed in the region; the later cloning effort identified BRCA1 itself. Both steps were necessary.
How BRCA1 changed breast cancer research
The impact of BRCA1 extended beyond identifying families at elevated risk. Once the gene was defined, researchers could ask what its protein does, how loss of function changes DNA repair, why some tissues are especially vulnerable, and whether the resulting defect creates a therapeutic weakness.
That chain of questions eventually connected hereditary cancer genetics to homologous recombination, genomic instability, and PARP-inhibitor strategies. In other words, a family-history observation became a molecular mechanism and then a treatment hypothesis.
What the BRCA1 discovery did not establish
BRCA1 and BRCA2 do not explain all hereditary breast cancer, and inherited variants do not account for most breast cancers overall. Other susceptibility genes and non-genetic factors also contribute to risk.
The discovery also did not turn genetic risk into certainty. A harmful variant raises risk; it does not determine that cancer will occur. Genetic counseling remains important because test results can have implications for both the person tested and biological relatives. NCI: BRCA Gene Changes
What the discovery teaches about scientific evidence
The BRCA1 story is a reminder that major advances often require different types of evidence to connect. Epidemiology identified a pattern. Genetics mapped the pattern. Molecular biology identified the gene. Functional experiments explained the repair defect. Clinical studies tested what that biology could mean for prevention and treatment.
Mary-Claire King’s contribution helped make inherited susceptibility a specific biological question that researchers could test. Read alongside other breast cancer research milestones, the story shows why mapping, gene identification, functional experiments, and clinical studies are distinct but connected achievements.
This article is intended for scientific education and does not provide individualized medical advice, diagnosis, or treatment recommendations.
